TH174396A - Fc-containing polypeptides with modified glycosylation And reduce the work of the effect - Google Patents

Abstract

Amendment to the Invention Summary 5/6/2015 Provided are binding polypeptides (e.g., antibodies) and drug conjugates thereof, comprising Fc domains having a modified glycosylation pattern and reduced effector function, in a particular embodiment the Fc domain comprises: an asparagine segment at amino acid position 298, according to EU numbering, and a serine or threonine segment at amino acid position 300, according to EU numbering; also provided are nucleic acids encoding the antigen-binding polypeptide, recombinant expression vectors, and host cells for generating such antigen-binding polypeptide. Methods of using the antigen-binding polypeptides disclosed herein for therapeutic purposes are also provided. ----------------------------------------------------------------------------- Provided are binding polypeptides (e.g., antibodies) and drug conjugates thereof. It comprises an Fc domain with a modified glycosylation profile and reduced effector function. In its characteristic form, the FC domain comprises an asparagine residue at amino acid position 298 according to the FU numbering designation and a serine or threonine residue at amino acid position 300 according to the EU designation. It is still being provided as a nucleic acid expressing antigen-binding polypeptide, a recombinant expression vector, and host cells for the production of such antigen-binding polypeptide. Methods of using the disclosed antigen-binding polypeptide for therapeutic purposes are still being provided.

Claims (1)

: Amendment to the invention summary 5/6/2015 provided are binding polypeptides (e.g., antibodies) and drug conjugates thereof, comprising Fc domains having a modified glycosylation pattern and reduced effector function, in a particular embodiment the Fc domain comprises: an asparagine segment at amino acid position 298, according to EU numbering, and a serine or threonine segment at amino acid position 300, according to EU numbering; also a nucleic acid encoding the antigen-binding polypeptide, a recombinant expression vector, and host cells for generating such antigen-binding polypeptide. Methods of using the antigen-binding polypeptide disclosed herein for therapeutic purposes are also provided. ----------------------------------------------------------------------------- Provided are binding polypeptides (e.g., antibodies) and drug conjugates thereof. It comprises an Fc domain with a modified glycosylation profile and reduced effector function. In its characteristic form, the FC domain comprises an asparagine residue at amino acid position 298 according to the FU designation and a serine or threonine residue at amino acid position 300 according to the EU designation. It remains available as a nucleic acid coding antigen-binding polypeptide, a recombinant expression vector, and host cells for the production of such antigen-binding polypeptide. The method of using the antigen-binding polypeptide disclosed herein for therapeutic purposes remains the claim (one) which appears on the advertisement page: Edited September 13, 2017 1. The isolated binding polypeptide comprises an Fc domain with altered glycosylation, where the Fc domain comprises: an asparagine segment at amino acid position 298, according to EU numbering, and a serine or threonine segment at amino acid position 300, according to EU numbering, and where the binding polypeptide exhibits reduced effector activity due to such altered glycosylation. &nTags: Pharmaceutical Patents